Financials

Charles River Laboratories International Inc. financials

CRL Life Sciences Tools and Services

Charles River Laboratories International Inc., founded in 1947 and headquartered in Wilmington, Massachusetts, United States, is a premier contract research organization providing comprehensive preclinical and clinical laboratory services. The company’s flagship offerings include in vivo and in vitro testing, toxicology studies, and integrated preclinical development solutions under its CRL Discovery Services. Under the leadership of CEO James C. Foster since 2017, CRL has secured a leading position in the global CRO market with an estimated 15% market share in its preclinical segment. Focused on digital transformation and strategic growth initiatives, the company is poised to achieve an anticipated annual revenue growth of 8-10%.

Snapshot

Charles River Laboratories International Inc. reported $4.02B in revenue in fiscal 2025, up -0.9% year over year, with an operating margin of 0.6%.

Revenue (FY2025): $4.02B
YoY growth: +-0.9%
Operating margin: 0.6%
Direction: Expanding

Financial statements

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenues	4,015,380	4,049,990	4,129,410	3,976,060
Cost of Sales	2,692,110	2,718,170	2,626,850	2,513,410
Gross Profit	1,323,280	1,331,820	1,502,560	1,462,650
Selling, General & Administrative Expenses	743,073	751,003	747,855	665,098
Depreciation & Amortization Expenses	179,066	138,471	137,440	146,578
Other Operating Expenses	375,974	215,000	—	—
Operating Profit	25,162	227,347	617,261	650,975
Interest and Investment Income	4,940	8,575	5,196	780
Interest Expense	(107,029)	(126,288)	(136,710)	(59,291)
Non-Operating Income	(22,576)	(16,520)	95,537	30,523
Total Non-Operating Income	(124,665)	(134,233)	(35,977)	(27,988)
Income Before Provision for Income Taxes	(99,503)	93,114	581,284	622,987
Provision for Income Taxes	42,660	67,823	100,914	130,379
Consolidated Net Income	(142,163)	25,291	480,370	492,608
Net Income Attributable to Minority Interests and Other	2,175	14,994	5,746	6,382
Net Income Attributable to Common Shareholders	(144,338)	22,203	474,624	486,226
Basic EPS	-2.91	0.43	9.27	9.57
Diluted EPS	-2.91	0.43	9.27	9.48
Basic Weighted Average Shares Outstanding	49,620	51,388	51,196	50,812
Diluted Weighted Average Shares Outstanding	49,620	51,388	51,196	51,301
Shares Outstanding	49,217	51,141	51,338	50,944

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Cash and Cash Equivalents	213,770	194,606	276,771	233,912
Total Cash and Cash Equivalents	213,770	194,606	276,771	233,912
Accounts Receivable	708,856	720,915	780,375	752,390
Total Trade Receivables	708,856	720,915	780,375	752,390
Inventories	299,103	278,544	380,259	255,809
Other Current Assets	225,320	209,006	171,257	196,921
Total Current Assets	1,447,050	1,403,070	1,608,660	1,439,030
Net Property, Plant & Equipment	2,016,630	2,016,500	2,033,770	1,857,420
Net Intangible Assets	339,995	723,400	864,051	955,275
Goodwill	2,764,250	2,846,610	3,095,050	2,849,900
Long-Term Investments	206,972	218,350	243,811	311,602
Other Long-Term Assets	360,519	320,412	349,662	189,541
Total Assets	7,135,420	7,528,350	8,195,000	7,602,770
Accounts Payable	148,800	140,337	168,937	205,915
Accrued Expenses	538,939	411,428	441,115	416,836
Unearned Revenue	210,418	248,322	241,820	264,259
Other Current Liabilities	222,158	194,014	203,210	204,575
Total Current Liabilities	1,120,320	994,101	1,055,080	1,091,590
Long-Term Debt	2,136,360	2,240,210	2,647,150	2,707,530
Leases	434,048	483,789	419,234	389,745
Other Long-Term Liabilities	233,505	302,172	414,540	390,404
Total Long-Term Liabilities	2,803,910	3,026,170	3,480,920	3,487,680
Total Liabilities	3,924,230	4,020,270	4,536,000	4,579,270
Common Stock	492	511	513	509
Additional Paid-in Capital	1,947,300	1,966,240	1,905,580	1,804,940
Accumulated Other Comprehensive Income	(171,783)	(317,345)	(196,427)	(262,057)
Retained Earnings	1,388,620	1,812,100	1,887,220	1,432,900
Total Common Shareholders' Equity	3,164,630	3,461,500	3,596,880	2,976,290
Minority Interests and Other	46,564	46,575	62,116	47,212
Total Shareholders' Equity	3,211,190	3,508,080	3,659,000	3,023,510
Total Liabilities and Shareholders' Equity	7,135,420	7,528,350	8,195,000	7,602,770

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Net Income	(142,163)	25,291	480,370	492,608
Depreciation & Amortization	403,312	361,741	314,124	303,870
Share-Based Compensation Expense	71,083	69,891	72,048	73,617
Other Adjustments	391,333	307,983	(80,264)	(97,901)
Changes in Trade Receivables	35,737	21,612	(33,434)	(150,570)
Changes in Inventories	(48,777)	16,804	(62,301)	(78,523)
Changes in Accounts Payable	2,869	(14,271)	(20,427)	(2,652)
Changes in Accrued Expenses	79,308	(27,604)	12,447	(42,164)
Changes in Unearned Revenue	(23,487)	25,125	(37,307)	88,115
Changes in Other Operating Activities	(31,569)	(51,995)	38,642	33,240
Cash from Operating Activities	737,646	734,577	683,898	619,640
Capital Expenditure	(219,152)	(232,967)	(318,528)	(324,733)
Purchases of Investments	(20,076)	(52,876)	(54,215)	(158,274)
Proceeds from Sale of Investments	9,102	41,687	6,667	4,549
Payments for Business Acquisitions	—	(5,479)	(194,785)	(283,392)
Proceeds from Business Divestments	17,441	—	—	163,275
Other Investing Activities	3,364	4,549	(2,294)	(9,347)
Cash from Investing Activities	(209,321)	(245,086)	(563,155)	(607,922)
Issuance of Long-Term Debt	1,227,530	1,081,580	776,353	2,952,430
Repayments of Long-Term Debt	(1,349,320)	(1,493,770)	(851,676)	(2,932,640)
Net Issuance / (Repayments) of Long-Term Debt	(121,783)	(412,188)	(75,323)	19,794
Issuance of Common Shares	714	23,878	25,597	25,110
Repurchases of Common Shares	(360,673)	(119,175)	(24,155)	(38,651)
Net Issuance / (Repurchases) of Common Shares	(359,959)	(95,297)	1,442	(13,541)
Other Financing Activities	(54,984)	(43,442)	(11,640)	(48,650)
Cash from Financing Activities	(536,726)	(550,927)	(85,521)	(42,397)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	18,828	(17,474)	8,044	25,579
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash	10,427	(78,910)	43,266	(5,100)

Key metrics

$9.82B

Market Cap

-68.58x

P/E

2.45x

P/S

28.52x

EV/EBITDA

-4.2%

Return on Equity

0.6%

Return on Invested Capital

1.29x

Current Ratio

12.9%

Free Cash Flow Margin

Quarterly trend

Quarter	Revenue	YoY growth	Operating margin	Operating income
Q1 2026	$996M	+1.2%	12.0%	$120M
Q4 2025	$994M	+-0.8%	-28.5%	$-283M
Q3 2025	$1.00B	+-0.5%	13.3%	$134M
Q2 2025	$1.03B	+0.6%	9.7%	$100M
Q1 2025	$984M	—	7.6%	$75M
Q4 2024	$1.00B	—	-16.7%	$-168M
Q3 2024	$1.01B	—	11.6%	$117M
Q2 2024	$1.03B	—	14.8%	$152M

Margins

33.0%

Gross margin

0.6%

Operating margin

-3.5%

Net margin

SourceCompany financial filings (income statement, balance sheet, cash flow) Last updated2026-06-20

Snapshot

Financial statements

Key metrics

Quarterly trend

Margins

More on Charles River Laboratories International Inc.

See how VectorShift works for your firm